ULTRAVIST 300 IN PLASTIC CONTAINER Drug Patent Profile

When do Ultravist 300 In Plastic Container patents expire, and when can generic versions of Ultravist 300 In Plastic Container launch?

Ultravist 300 In Plastic Container is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in ULTRAVIST 300 IN PLASTIC CONTAINER is iopromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iopromide profile page.

Summary for ULTRAVIST 300 IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ULTRAVIST 300 IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	ULTRAVIST 300 IN PLASTIC CONTAINER	iopromide	INJECTABLE;INJECTION	020220-005	Nov 18, 2008		DISCN	Yes	No

International Patents for ULTRAVIST 300 IN PLASTIC CONTAINER

See the table below for patents covering ULTRAVIST 300 IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	73199
Ireland	49647	NON-IONIC X-RAY CONTRAST AGENTS
Egypt	14530	NON-IONIC X-RAY CONTRAST AGENTS
Yugoslavia	61780
Canada	1130316	DIAMIDES D'ACIDE ISOPHTALIQUE TRI-IODES UTILISES COMME AGENTS DE CONTRASTE NON IONIQUES POUR RAYONS X (TRI-IODATED ISOPHTHALIC ACID DIAMIDES AS NON-IONIC X-RAY CONTRAST AGENTS)

ULTRAVIST 300 IN PLASTIC CONTAINER Market Analysis and Financial Projection

Last updated: February 9, 2026

What Is the Market Position of ULTRAVIST 300 in Plastic Containers?

ULTRAVIST 300, a contrast agent with iohexol as the active ingredient, is used primarily in medical imaging procedures such as computed tomography (CT) scans. It belongs to the class of iodinated contrast media, characterized by high viscosity and osmolality. The formulation in plastic containers aligns with contemporary packaging standards which favor safety, convenience, and cost-efficiency.

The drug's growth prospects are influenced by the global increase in diagnostic imaging procedures. With an aging population and rising prevalence of chronic diseases requiring imaging, demand for contrast agents like ULTRAVIST 300 is expected to track upwards.

What Are the Industry and Competitive Fundamentals?

Market Size and Growth: The global contrast media market was valued at approximately USD 3.4 billion in 2022, with a compound annual growth rate (CAGR) of roughly 4.8% expected through 2030.[1] High-end CT imaging, where ULTRAVIST 300 is used, drives a significant share.

Key Competitors: Major players include GE Healthcare (Omnipaque), Bracco (Xenetix), and Bayer (Iopamiro). ULTRAVIST 300’s differentiation hinges on its iodine concentration, stability profile, and safety.

Pricing Dynamics: Prices fluctuate based on formulation, container type, and regional regulations. Plastic container packaging reduces costs relative to glass, influencing pricing strategies.

What Are the Regulatory and Patent Landscape Factors?

ULTRAVIST 300 is approved in multiple markets, including the U.S. (FDA approval), European Union (EMA), and Asia. Patents covering manufacturing processes, composition, and specific container designs expire at different times, affecting competitive positioning.

Patent expirations are critical. For instance, Bayer’s composition patent for Iohexol expired in the late 2010s in some regions, opening generic manufacturing opportunities. However, brand loyalty, regulatory approvals, and specific packaging protection sustain market share.

What Are the Key Development and Commercial Strategies?

Research & Development: Ongoing R&D focuses on reducing osmolality, improving safety profiles, and developing lower-dose formulations. Innovations in plastic container design improve stability, reduce leaching, and enhance patient safety.

Market Expansion: Strategies target emerging markets with expanding healthcare infrastructure. Regulatory approvals in China, India, and Latin America increase access.

Partnerships and Licensing: Collaborations with regional distributors and OEM manufacturers strengthen distribution channels, especially in lower-income regions.

What Financially Impacts an Investment?

Revenue Trends: For Bayer, contrast media sales contributed around USD 1.2 billion in 2021, with ULTRAVIST 300 representing a significant sharing of this segment.[2] Market expansion and patent expirations influence sales trajectories.

Profit Margins: Margins depend on manufacturing costs, pricing strategies, and competition. Plastic container packaging lowers logistics costs but requires investment in manufacturing lines.

Risks: Regulatory delays, adverse event reports, and competition from generic entrants pose risks. Patent cliffs may lead to erosion of profit margins unless brand differentiation persists.

What Are Critical Investment Considerations?

• Market Demand: Growing imaging procedures support demand, barring drastic healthcare policy changes.
• Patent and Regulatory Status: Patent expirations and approvals govern market exclusivity.
• Manufacturing Costs: Advances in container technology can lower costs.
• Competitive Landscape: Entry of generics can pressure prices; differentiation strategies are necessary.
• Regulatory Risks: Future safety concerns or legislative changes may impact market access.

Key Takeaways

• ULTRAVIST 300 is positioned within a growing segment of the contrast media market driven by increasing diagnostic imaging.
• Competition is intense; patent expirations facilitate generic entry but brand loyalty and regulatory approvals provide protection.
• Packaging in plastic containers reduces costs and aligns with safety standards but requires ongoing R&D investment.
• Market expansion into emerging economies offers growth opportunities but entails regulatory complexities.
• Financial performance depends heavily on market share, pricing, manufacturing efficiencies, and patent landscape.

FAQs

1. How does ULTRAVIST 300 compare to competing contrast agents?
ULTRAVIST 300 offers high iodine concentration and good safety profile. Its differentiation largely depends on formulation stability and packaging, but generic competition is intense post-patent expiry.

2. What regulatory hurdles could affect ULTRAVIST 300’s sales?
Potential hurdles include safety concerns related to iodinated contrast agents, updated medical guidelines, and regional approval delays. Post-market surveillance data also impacts regulatory standing.

3. What impact does packaging technology have on the drug’s market viability?
Plastic containers reduce manufacturing and distribution costs, improve safety and convenience, and meet regulatory standards. They also influence user perception and market differentiation.

4. Are there any recent innovations related to ULTRAVIST 300?
Research is ongoing into lower osmolality formulations and alternative delivery systems, such as pre-filled syringes. Innovations aim to improve safety and patient comfort.

5. How sensitive is ULTRAVIST 300 to patent expirations?
Patent expiration allows generic manufacturers to enter markets, leading to price reductions and increased competition. Brand differentiation and region-specific patent protection mitigate this impact temporarily.

---

Sources

[1] MarketsandMarkets, "Contrast Media Market," 2022.
[2] Bayer Annual Report, 2021.